Deal continues consolidation trend, based on portfolio expansion and simplifying supply chains

US-based generic drugmakers Amneal and Impax have agreed to merge, through an all-shares deal that the companies claim will push the combined firm into the top five US generics firms by revenue.

The new Amneal will have a strengthened supply chain and an expanded product portfolio, with around 165 product families on the market, and a further 300 in development across a broad range of therapeutic areas and dosage forms. The companies also expect to be able to make $200 million (£150 million) in annual cost savings within two years of completing the deal.